Literature DB >> 28131848

Dehydroandrographolide inhibits oral cancer cell migration and invasion through NF-κB-, AP-1-, and SP-1-modulated matrix metalloproteinase-2 inhibition.

Ming-Ju Hsieh1, Jui-Chieh Chen2, Wei-En Yang3, Su-Yu Chien4, Mu-Kuan Chen5, Yu-Sheng Lo6, Yi-Ting Hsi6, Yi-Ching Chuang6, Chia-Chieh Lin6, Shun-Fa Yang7.   

Abstract

BACKGROUND AND
PURPOSE: Oral cancer is a type of head and neck cancer that is characterized by cancerous tissue growth in the oral cavity. Andrographolide and dehydroandrographolide (DA) are the two principal components of Andrographis paniculata (Burm.f.) Nees and are the main contributors to its therapeutic properties. However, the pharmacological activities of DA remain unclear. EXPERIMENTAL APPROACH: In this study, we used wound closure assay and Boyden chamber assay to determine the effects of DA on oral cancer cell migration and invasion. KEY
RESULTS: DA treatment significantly inhibited the migration and invasion abilities of SCC9 cells in vitro. Gelatin zymography and Western blotting results revealed that DA inhibited MMP-2 activity and reduced its protein levels. DA inhibited the phosphorylation of ERK1/2, p38, and JNK 1/2 in SCC9 cells. According to the mRNA levels detected using real-time PCR, DA inhibited MMP-2 expression in SCC9 cells. This inhibitory effect was associated with the upregulation of the TIMP-2 and downregulation of NF-κB, AP-1, and SP-1 expression. In addition, DA suppressed carcinoma-associated epithelial-mesenchymal transition in SCC9 cells. Finally, DA administration effectively suppressed MMP-2 expression and tumor metastases in the oral carcinoma xenograft mouse model in vivo. CONCLUSIONS & IMPLICATIONS: DA inhibits the invasion of human oral cancer cells and is a potential chemopreventive agent against oral cancer metastasis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dehydroandrographolide; Invasion; Matrix metalloproteinase-2; Migration; Oral cancer

Mesh:

Substances:

Year:  2017        PMID: 28131848     DOI: 10.1016/j.bcp.2017.01.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor-κB-dependent pathway.

Authors:  Tian Liu; Tian Long; Haosen Li
Journal:  Exp Ther Med       Date:  2021-01-11       Impact factor: 2.447

2.  Coronarin D induces reactive oxygen species-mediated cell death in human nasopharyngeal cancer cells through inhibition of p38 MAPK and activation of JNK.

Authors:  Jui-Chieh Chen; Ming-Chang Hsieh; Shu-Hui Lin; Chia-Chieh Lin; Yi-Ting Hsi; Yu-Sheng Lo; Yi-Ching Chuang; Ming-Ju Hsieh; Mu-Kuan Chen
Journal:  Oncotarget       Date:  2017-11-14

3.  Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1/2-mediated matrix metalloproteinase-2 expression.

Authors:  Shih-Liang Yang; Fu-Hsuan Kuo; Pei-Ni Chen; Yi-Hsien Hsieh; Nuo-Yi Yu; Wei-En Yang; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-11-11

4.  Overexpression of carbonic anhydrase IX induces cell motility by activating matrix metalloproteinase-9 in human oral squamous cell carcinoma cells.

Authors:  Jia-Sin Yang; Chiao-Wen Lin; Yi-Hsien Hsieh; Ming-Hsien Chien; Chun-Yi Chuang; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-08-12

Review 5.  Melatonin as a potential inhibitory agent in head and neck cancer.

Authors:  Chia-Ming Yeh; Shih-Chi Su; Chiao-Wen Lin; Wei-En Yang; Ming-Hsien Chien; Russel J Reiter; Shun-Fa Yang
Journal:  Oncotarget       Date:  2017-08-09

6.  The anti-alcohol dependency drug disulfiram inhibits the viability and progression of gastric cancer cells by regulating the Wnt and NF-κB pathways.

Authors:  Jun Zhang; Ke Pu; Suyang Bai; Yukui Peng; Fan Li; Rui Ji; Qinghong Guo; Weiming Sun; Yuping Wang
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

7.  Src Is a Prime Target Inhibited by Celtis choseniana Methanol Extract in Its Anti-Inflammatory Action.

Authors:  Han Gyung Kim; Subin Choi; Jongsung Lee; Yo Han Hong; Deok Jeong; Keejung Yoon; Deok Hyo Yoon; Gi-Ho Sung; Seungihm Lee; Suntaek Hong; Young-Su Yi; Jong-Hoon Kim; Jae Youl Cho
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-14       Impact factor: 2.629

8.  AP-1 confers resistance to anti-cancer therapy by activating XIAP.

Authors:  Yuan Wang; Guo-Hui Wan; Ying-Min Wu; Hong-Sheng Wang; Hai-Fang Wang; Ge Zhang; Lin-Lin Lu; Zi-Qian Li; Ka-Ying Chan; Yan Zhou; Shao-Hui Cai; Yi-Fei Qi; Jun Du
Journal:  Oncotarget       Date:  2018-01-03

9.  Silencing of c-jun decreases cell migration, invasion, and EMT in radioresistant human nasopharyngeal carcinoma cell line CNE-2R.

Authors:  Guoxiang Lin; Binbin Yu; Zhongguo Liang; Ling Li; Song Qu; Kaihua Chen; Lei Zhou; Qiteng Lu; Yongchu Sun; Xiaodong Zhu
Journal:  Onco Targets Ther       Date:  2018-07-04       Impact factor: 4.147

10.  Chamaejasmin B Decreases Malignant Characteristics of Mouse Melanoma B16F0 and B16F10 Cells.

Authors:  Lingling Si; Xinyan Yan; Yan Wang; Boxue Ren; Huanhuan Ren; Yangfang Ding; Qiusheng Zheng; Defang Li; Ying Liu
Journal:  Front Oncol       Date:  2020-04-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.